Header Logo

Connection

Robin Jones to Sarcoma

Back to Details
This is a "connection" page, showing publications Robin Jones has written about Sarcoma.
Robin Jones
Connection Strength
22.083
Sarcoma
  1. Management of Vascular Sarcoma. Surg Oncol Clin N Am. 2022 07; 31(3):485-510.
    View in: PubMed
    Score: 0.682
  2. The evolving management of epithelioid sarcoma. Eur J Cancer Care (Engl). 2021 Nov; 30(6):e13489.
    View in: PubMed
    Score: 0.638
  3. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med. 2021 06; 10(11):3565-3574.
    View in: PubMed
    Score: 0.629
  4. Current Reality of Treating Advanced Soft Tissue Sarcoma as Illustrated by Case Studies. Oncology. 2021; 99 Suppl 1:8-16.
    View in: PubMed
    Score: 0.627
  5. Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. Clin Cancer Res. 2021 07 15; 27(14):3861-3866.
    View in: PubMed
    Score: 0.621
  6. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Mol Cancer Ther. 2021 01; 20(1):132-141.
    View in: PubMed
    Score: 0.609
  7. Sirolimus for patients with progressive epithelioid hemangioendothelioma. Cancer. 2021 02 15; 127(4):504-506.
    View in: PubMed
    Score: 0.607
  8. Gynecological Sarcomas: Molecular Characteristics, Behavior, and Histology-Driven Therapy. Int J Surg Pathol. 2021 Feb; 29(1):4-20.
    View in: PubMed
    Score: 0.602
  9. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 2020 08; 5(4).
    View in: PubMed
    Score: 0.597
  10. Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. JCO Glob Oncol. 2020 07; 6:1046-1051.
    View in: PubMed
    Score: 0.594
  11. Ewing-like sarcomas: New molecular diagnoses in need of optimized treatment approaches. Indian J Med Res. 2019 12; 150(6):521-523.
    View in: PubMed
    Score: 0.570
  12. Negative phase III trials announce the need for biomarkers in sarcoma. Eur J Cancer. 2019 12; 123:81-82.
    View in: PubMed
    Score: 0.566
  13. Sarcomas and old age: few options for such a large patient population. Future Oncol. 2019 Sep; 15(26s):11-15.
    View in: PubMed
    Score: 0.561
  14. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 2019 07 15; 125(14):2445-2454.
    View in: PubMed
    Score: 0.547
  15. Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. Anticancer Res. 2019 Jan; 39(1):347-351.
    View in: PubMed
    Score: 0.535
  16. Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas. Expert Rev Anticancer Ther. 2018 12; 18(12):1241-1248.
    View in: PubMed
    Score: 0.525
  17. Quality of life and patients' expectations in soft tissue sarcoma. Future Oncol. 2018 May; 14(10s):51-62.
    View in: PubMed
    Score: 0.511
  18. The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncol. 2018 May; 14(12):1197-1211.
    View in: PubMed
    Score: 0.510
  19. Olaratumab in soft tissue sarcoma - Current status and future perspectives. Eur J Cancer. 2018 03; 92:33-39.
    View in: PubMed
    Score: 0.502
  20. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. Am J Clin Oncol. 2018 02; 41(2):147-151.
    View in: PubMed
    Score: 0.502
  21. Sarcoma: Does histotype-tailored neoadjuvant therapy improve outcomes? Nat Rev Clin Oncol. 2017 10; 14(10):589-590.
    View in: PubMed
    Score: 0.486
  22. Olaratumab for the treatment of soft-tissue sarcoma. Future Oncol. 2017 Oct; 13(24):2151-2157.
    View in: PubMed
    Score: 0.484
  23. Treatment of retroperitoneal sarcoma: current standards and new developments. Curr Opin Oncol. 2017 07; 29(4):260-267.
    View in: PubMed
    Score: 0.482
  24. Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here? Lancet Oncol. 2017 06; 18(6):706-707.
    View in: PubMed
    Score: 0.479
  25. Phase III Soft Tissue Sarcoma Trials: Success or Failure? Curr Treat Options Oncol. 2017 03; 18(3):19.
    View in: PubMed
    Score: 0.471
  26. Treatment of soft tissue sarcoma: a focus on earlier stages. Future Oncol. 2017 Jan; 13(1s):13-21.
    View in: PubMed
    Score: 0.466
  27. Understanding sarcomas and other rare tumors: an interview with Robin L Jones. Future Oncol. 2017 Feb; 13(5):391-394.
    View in: PubMed
    Score: 0.464
  28. Drug repositioning in sarcomas and other rare tumors. EBioMedicine. 2016 Apr; 6:4-5.
    View in: PubMed
    Score: 0.441
  29. Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors. Int J Surg Pathol. 2016 Feb; 24(1):5-15.
    View in: PubMed
    Score: 0.426
  30. Current and advancing systemic treatment options for soft tissue sarcomas. Expert Opin Pharmacother. 2015; 16(13):2023-37.
    View in: PubMed
    Score: 0.405
  31. Analysis of clinical prognostic factors for adult patients with head and neck sarcomas. Otolaryngol Head Neck Surg. 2014 Dec; 151(6):976-83.
    View in: PubMed
    Score: 0.398
  32. New drugs and clinical trial design in advanced sarcoma: have we made any progress? Future Oncol. 2013 Oct; 9(10):1409-11.
    View in: PubMed
    Score: 0.366
  33. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug; 35(4):351-7.
    View in: PubMed
    Score: 0.343
  34. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemother Pharmacol. 2011 Aug; 68(2):423-9.
    View in: PubMed
    Score: 0.304
  35. Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Ann Surg Oncol. 2022 Nov; 29(12):7335-7348.
    View in: PubMed
    Score: 0.170
  36. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. Eur J Cancer. 2022 08; 171:183-192.
    View in: PubMed
    Score: 0.170
  37. Risk factors for the development of local recurrence in extremity soft-tissue sarcoma. Expert Rev Anticancer Ther. 2022 Jan; 22(1):83-95.
    View in: PubMed
    Score: 0.164
  38. Treatments and Outcomes in Oligometastatic Soft Tissue Soft Sarcoma - A Single Centre Retrospective Analysis. Anticancer Res. 2021 Oct; 41(10):5089-5096.
    View in: PubMed
    Score: 0.162
  39. Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma. Future Oncol. 2021 Sep; 17(27):3627-3636.
    View in: PubMed
    Score: 0.161
  40. Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas. Cells. 2021 06 17; 10(6).
    View in: PubMed
    Score: 0.159
  41. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021 08 15; 127(16):2934-2942.
    View in: PubMed
    Score: 0.157
  42. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Med. 2021 04; 10(8):2645-2659.
    View in: PubMed
    Score: 0.156
  43. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. Oncoimmunology. 2020 11 19; 9(1):1847846.
    View in: PubMed
    Score: 0.152
  44. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Nov 01; 6(11):1778-1782.
    View in: PubMed
    Score: 0.152
  45. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432.
    View in: PubMed
    Score: 0.151
  46. SMARCA4-Deficient Thoracic Sarcoma. Int J Surg Pathol. 2021 Sep; 29(6):640-641.
    View in: PubMed
    Score: 0.148
  47. Health-related quality Of Life In patients with advanced Soft TIssue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort study. BMJ Open. 2020 06 01; 10(6):e035171.
    View in: PubMed
    Score: 0.148
  48. Metastatic Soft Tissue Sarcomas in Adolescents and Young Adults: A Specialist Center Experience. J Adolesc Young Adult Oncol. 2020 12; 9(6):628-638.
    View in: PubMed
    Score: 0.147
  49. Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. Expert Rev Anticancer Ther. 2020 04; 20(sup1):15-28.
    View in: PubMed
    Score: 0.147
  50. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA. 2020 04 07; 323(13):1266-1276.
    View in: PubMed
    Score: 0.146
  51. Imaging Soft-tissue Sarcomas of the Head and Neck: A Tertiary Soft-tissue Sarcoma Unit Experience. Anticancer Res. 2019 Nov; 39(11):6223-6230.
    View in: PubMed
    Score: 0.142
  52. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020 01 01; 126(1):98-104.
    View in: PubMed
    Score: 0.141
  53. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clin Cancer Res. 2019 10 01; 25(19):5808-5817.
    View in: PubMed
    Score: 0.138
  54. Aldoxorubicin in soft tissue sarcomas. Future Oncol. 2019 May; 15(13):1429-1435.
    View in: PubMed
    Score: 0.136
  55. Age-related sarcoma patient experience: results from a national survey in England. BMC Cancer. 2018 Oct 17; 18(1):991.
    View in: PubMed
    Score: 0.132
  56. Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Med Oncol. 2018 Sep 05; 35(11):138.
    View in: PubMed
    Score: 0.131
  57. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. JAMA Oncol. 2018 09 01; 4(9):e180219.
    View in: PubMed
    Score: 0.131
  58. Pancreaticoduodenectomy for the Management of Pancreatic or Duodenal Metastases from Primary Sarcoma. Anticancer Res. 2018 Jul; 38(7):4041-4046.
    View in: PubMed
    Score: 0.129
  59. Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. AJR Am J Roentgenol. 2018 Jan; 210(1):175-182.
    View in: PubMed
    Score: 0.123
  60. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 08; 18(8):1089-1103.
    View in: PubMed
    Score: 0.120
  61. The Current Landscape of Early Drug Development for Patients With Sarcoma. Am Soc Clin Oncol Educ Book. 2017; 37:807-810.
    View in: PubMed
    Score: 0.116
  62. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 11 10; 34(32):3898-3905.
    View in: PubMed
    Score: 0.114
  63. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97.
    View in: PubMed
    Score: 0.112
  64. Epithelioid Sarcoma: Diagnostic Features and Genetics. Adv Anat Pathol. 2016 Jan; 23(1):41-9.
    View in: PubMed
    Score: 0.109
  65. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013 Dec 15; 19(24):6902-11.
    View in: PubMed
    Score: 0.093
  66. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 2010 May-Jun; 16(3):183-94.
    View in: PubMed
    Score: 0.073
  67. EWSR1-SMAD3-Positive Fibroblastic Tumor. Int J Surg Pathol. 2021 Apr; 29(2):179-181.
    View in: PubMed
    Score: 0.037
  68. Superficial CD34-Positive Fibroblastic Tumor. Int J Surg Pathol. 2020 Dec; 28(8):879-881.
    View in: PubMed
    Score: 0.037
  69. Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells. Br J Cancer. 2016 08 09; 115(4):473-9.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.